Cavion fetches $26.1 mln
Cavion Inc, a biotech company focused on developing new treatments for neurological and oncologic diseases, has raised $26.1 million in funding. The investors included Lilly Ventures, Novartis Venture Fund and Enso Ventures.
9 January 2017•1 min read
